Effects on Serum Uric Acid by Difference of the Renal Protective Effects with Atorvastatin and Rosuvastatin in Chronic Kidney Disease Patients

被引:13
作者
Kose, Eiji [1 ]
An, Taesong [3 ]
Kikkawa, Akihiko [3 ]
Matsumoto, Yoshiaki [2 ]
Hayashi, Hiroyuki [1 ]
机构
[1] Nihon Univ, Sch Pharm, Dept Pharmacotherapy, Funabashi, Chiba 2748555, Japan
[2] Nihon Univ, Sch Pharm, Dept Clin Pharmacokinet, Funabashi, Chiba 2748555, Japan
[3] Yokosuka Kyousai Hosp, Yokosuka, Kanagawa 2388588, Japan
关键词
chronic kidney disease (CKD) stages 3; hyperuricemia; hyperlipidemia; Atorvastatin; Rosuvastatin; CORONARY-HEART-DISEASE; URATE TRANSPORTER; FENOFIBRATE; HYPERURICEMIA; PROGRESSION; THERAPY; STATINS; PEOPLE; IMPACT; LEVEL;
D O I
10.1248/bpb.b13-00418
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hyperuricemia and hyperlipidemia have attracted attention as progression factors for chronic kidney disease (CKD). In the drug treatment of hyperuricemia and hyperlipidemia complications, Atorvastatin (ATV), which inhibits urinary protein, increases glomerular filtration rate (GFR) and has renal protective effects, and Rosuvastatin (ROS) were found be suitable because they promote serum uric acid (SUA) excretion. However, these drugs were administered at very high doses in previous studies. In this study, we have investigated the effects of ATV or ROS on renal protective effects and their SUA levels before and three months after each drug administration in CKD patients. We retrospectively investigated outpatients presenting with CKD (stages 3) on the basis of their electronic medical records as subjects. Estimated GFR (eGFR) was significantly increased after ATV administration, whereas no change in eGFR was observed following ROS administration. Furthermore, SUA levels significantly decreased after ATV administration, whereas no changes were observed following ROS administration. Therefore, it may be not necessary to administer drugs that lower the SUA levels to patients presenting with hyperuricemia and hyperlipidemia complications associated with moderate renal failure, such as patients with at least stage 3 CKD. We consider that, by selecting ATV, the renal protective effects and SUA-lowering effect would be sufficient.
引用
收藏
页码:226 / 231
页数:6
相关论文
共 50 条
[21]   Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis [J].
Sanguankeo, Anawin ;
Upala, Sikarin ;
Cheungpasitporn, Wisit ;
Ungprasert, Patompong ;
Knight, Eric L. .
PLOS ONE, 2015, 10 (07) :e0132970
[22]   The effects of treatment with atorvastatin versus rosuvastatin on endothelial dysfunction in patients with hyperlipidaemia [J].
Demir, Vahit ;
Dogru, Mehmet Tolga ;
Ede, Huseyin ;
Yilmaz, Samet ;
Alp, Caglar ;
Celik, Yunus ;
Yidirim, Nesligul .
CARDIOVASCULAR JOURNAL OF AFRICA, 2018, 29 (03) :162-166
[23]   Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease [J].
Fassett, Robert G. ;
Robertson, Iain K. ;
Ball, Madeleine J. ;
Geraghty, Dominic P. ;
Coombes, Jeff S. .
CLINICAL NEPHROLOGY, 2014, 81 (02) :75-85
[24]   Serum Uric Acid, the Metabolic Syndrome, and the Risk of Chronic Kidney Disease in Patients with Type 2 Diabetes [J].
Sheikhbahaei, Sara ;
Fotouhi, Akbar ;
Hafezi-Nejad, Nima ;
Nakhjavani, Manouchehr ;
Esteghamati, Alireza .
METABOLIC SYNDROME AND RELATED DISORDERS, 2014, 12 (02) :102-109
[25]   Serum Uric Acid Levels and Incident Chronic Kidney Disease in Patients With Type 2 Diabetes and Preserved Kidney Function [J].
Zoppini, Giacomo ;
Targher, Giovanni ;
Chonchol, Michel ;
Ortalda, Vittorio ;
Abaterusso, Cataldo ;
Pichiri, Isabella ;
Negri, Carlo ;
Bonora, Enzo .
DIABETES CARE, 2012, 35 (01) :99-104
[26]   The association of renal tubular inflammatory and injury markers with uric acid excretion in chronic kidney disease patients [J].
Zheng, Yuqi ;
Guan, Haochen ;
Zhou, Xun ;
Xu, Ying ;
Fu, Chensheng ;
Xiao, Jing ;
Ye, Zhibin .
INTERNATIONAL UROLOGY AND NEPHROLOGY, 2020, 52 (05) :923-932
[27]   The effects of atorvastatin and rosuvastatin on exercise tolerance in patients with coronary heart disease [J].
Liu, Dan ;
Shen, Tao ;
Ren, Chuan ;
Xu, Shunlin ;
Zhou, Lequn ;
Bai, Jin ;
Li, Nan ;
Zhao, Wei ;
Gao, Wei .
EXPERT OPINION ON DRUG SAFETY, 2020, 19 (09) :1203-1208
[28]   Uric acid and incident chronic kidney disease in dyslipidemic individuals [J].
Barkas, Fotios ;
Elisaf, Moses ;
Liberopoulos, Evangelos ;
Kalaitzidis, Rigas ;
Liamis, George .
CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (07) :1193-1199
[29]   Threshold Effects of Serum Uric Acid on Chronic Kidney Disease in US Women without Hypertension and Diabetes: A Cross-Sectional Study [J].
Hu, Guiping ;
Bai, Yi ;
Chen, Tian ;
Tang, Shichuan ;
Hu, Lihua .
KIDNEY & BLOOD PRESSURE RESEARCH, 2019, 44 (05) :1036-1049
[30]   Serum uric acid and chronic kidney disease: the Severance cohort study [J].
Mok, Yejin ;
Lee, Sun Ju ;
Kim, Myoung Soo ;
Cui, Wenying ;
Moon, Young Myoung ;
Jee, Sun Ha .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (05) :1831-1835